Adrenalin Mylan Stungulyf, lausn 1 mg/ml Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

adrenalin mylan stungulyf, lausn 1 mg/ml

viatris limited - adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 1 mg/ml

Carbocain adrenalin Stungulyf, lausn 10 mg + 5 µg/ml Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

carbocain adrenalin stungulyf, lausn 10 mg + 5 µg/ml

aspen pharma trading limited - mepivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 10 mg + 5 µg/ml

Jext Stungulyf, lausn í áfylltum lyfjapenna 150 míkróg Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

jext stungulyf, lausn í áfylltum lyfjapenna 150 míkróg

alk-abelló a/s - adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn í áfylltum lyfjapenna - 150 míkróg

Jext Stungulyf, lausn í áfylltum lyfjapenna 300 míkróg Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

jext stungulyf, lausn í áfylltum lyfjapenna 300 míkróg

alk-abelló a/s - adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn í áfylltum lyfjapenna - 300 míkróg

Marcain adrenalin Stungulyf, lausn 2,5 mg/ml+5 míkróg/m Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain adrenalin stungulyf, lausn 2,5 mg/ml+5 míkróg/m

aspen pharma trading limited - bupivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 2,5 mg/ml+5 míkróg/m

Marcain adrenalin Stungulyf, lausn 5 mg/ml+5 míkróg/ml Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain adrenalin stungulyf, lausn 5 mg/ml+5 míkróg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 5 mg/ml+5 míkróg/ml

Xylocain adrenalin Stungulyf, lausn 10 mg/ml+5 míkróg/ml Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

xylocain adrenalin stungulyf, lausn 10 mg/ml+5 míkróg/ml

aspen pharma trading limited - lidocainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 10 mg/ml+5 míkróg/ml

Xylocain Dental adrenalin Stungulyf, lausn 20 mg/ml+12,5 míkróg/ml Izland - izlandi - LYFJASTOFNUN (Icelandic Medicines Agency)

xylocain dental adrenalin stungulyf, lausn 20 mg/ml+12,5 míkróg/ml

dentsply detrey gmbh* - adrenalinum bítartrat (epinephrinum bítartrat); lidocainum hýdróklóríð - stungulyf, lausn - 20 mg/ml+12,5 míkróg/ml

BiResp Spiromax Európai Unió - izlandi - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lyf til veikindi öndunarvegi sjúkdómum, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

DuoResp Spiromax Európai Unió - izlandi - EMA (European Medicines Agency)

duoresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lyf til veikindi öndunarvegi sjúkdómum, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).